Highlights Moderna, Inc.

Stocks

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 17/07/2026 BST			5-day change	1st Jan Change
61.82 ^USD	-2.11%		-9.45%	+109.63%

07-16	Moderna advances its cancer therapy assessment, but the stock slides
07-16	Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech -- Update	DJ

Highlights

06-26	Health Care Up on Rotation Into Laggards -- Health Care Roundup	DJ
06-23	Moderna Receives Unanimous FDA Panel Recommendation for mRNA-Based Influenza Vaccine for Adults 50 and Older	CI
06-18	Moderna's Flu Shot Wins Support From FDA Advisers	MT
06-18	US FDA advisers vote in favor of Moderna's flu vaccine	RE
06-17	Moderna Plans Multiple Product Launches in 2027 and 2028	CI
06-16	Moderna announces executive changes ahead of potential launches	RE
06-09	Moderna Receives UK Authorization to Evaluate Cancer Vaccine for Lynch Syndrome	MT
06-03	HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery	RE
05-21	Moderna's Experimental Flu Shot to Be Reviewed by FDA Panel in June	MT
05-21	Moderna's Experimental Flu Shot to be Reviewed by FDA Panel in June, Bloomberg Reports	MT
05-06	Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial	RE
05-01	Tranche Update on Moderna, Inc.'s Equity Buyback Plan announced on August 3, 2022.	CI
05-01	Moderna, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-01	Moderna Maintains 2026 Revenue Growth Outlook as First-Quarter Results Beat Estimates	MT
05-01	Moderna, Inc. Provides Earnings Guidance for the Second Quarter and Reiterates Earnings Guidance for Full Year 2026	CI
05-01	Moderna Q1 Loss Widens, Revenue Rises; Reiterates 2026 Revenue Outlook	MT
05-01	Earnings Flash (MRNA) Moderna Posts Q1 Loss $3.40 a Share, vs. FactSet Est of $4.45 Loss	MT
05-01	Moderna reports Q1 EPS of $ -3.40	RE
05-01	Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales	RE
05-01	Earnings Flash (MRNA) Moderna, Inc. Reports Q1 Revenue $389.0M, vs. FactSet Est of $236.4M	MT
05-01	Moderna tops revenue estimates on stronger international COVID vaccine sales	RE
04-27	Moderna Faces Fresh Patent Challenge From CureVac Over COVID Shot	MT
04-24	CureVac sues Moderna for patent infringement over COVID-19 vaccines	RE
04-21	Moderna receives European Commission marketing authorization for mCOMBRIAX	RE
04-21	Moderna Says European Commission Grants Marketing Authorization for mCombriax Vaccine for Influenza, COVID-19	MT